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1. Introduction 
Looking back to history, the first accredited description of melanoma appeared in the 
writings of Hippocrates (5th century, BC) as a “fatal black disease”; over the centuries, 
several other physicians have described pigmented malignant skin lesions, but only during 
the 1800s significant gains were obtained in the comprehension and treatment of melanoma. 
In 1820 William Norris suggested for the first time a genetic basis for the disease, reporting 
the development of a skin neoplasm in a father and his son, and in 1838 Carswell used the 
medical term “melanoma” to describe pigmented lesions.  
Cutaneous melanoma represents a malignant skin cancer, which arises from the neoplastic 
transformation of specialized pigment-producing cells, the melanocytes. Its aggressive 
features, in terms of tendency to develop metastasis and strong resistance to therapy, make 
melanoma one of the deadliest forms of cancer. 
1.1 Origin and pathogenesis 
During embryogenesis, cellular precursors emerge from the neural crest and migrate to 
various sites, as uveal tracts, meninges, ectodermal mucosa and skin, where they finally 
establish to the epidermal-dermal junction, where they differentiate into melanocytes 
(Bennett, 1993), making dendridic contacts with the basal keratinocytes and thus forming 
the so called ”epidermal melanin unit”. The melanin produced by the melanocytes is 
transferred to keratinocytes for the adsorption and scattering of light radiation. The 
quantity of pigment dictates skin pigmentation and protection degree from UV-induced 
damage.  
1.1.1 Melanoma stages 
As reported in Figure 1, the pathogenesis of melanoma is characterized by a series of 
histological and molecular alterations; in particular, five distinct stages have been proposed 
for melanoma development (Chin, 2003): (I) acquired and/or congenital nevi represent 
benign forms of melanocytic proliferation, different from (II) dysplastic nevi with some 
degree of structural atypia and a deeper disorder in the melanin unit organization; both 
benign and dysplastic nevi may evolve to (III) radial growth phase melanoma, characterized 
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by a lateral growth, that remains mostly limited to the epidermis, due to the dependence of 
melanocyte proliferation from growth factors released by keratinocytes (in situ melanoma). 
Subsequently, melanoma can shift to (IV) vertical, mitogens- and anchorage-independent, 
growth phase, with dermis and subcutaneous tissue invasion, that, further on, may give rise 
to a (V) fully metastatic melanoma. These stages, describing melanoma natural history, have 
corresponding molecular counterparts, providing a biochemical basis for the main cellular 
events responsible for melanomagenesis. Accordingly, mutations in genes, normally 
regulating proliferation, differentiation and cell death, are involved in all of the main steps 
of melanoma progression, as briefly summarized in Figure 1. 
1.1.2 Clinical forms 
The vast majority of melanomas arise from cutaneous sites and different clinical forms have 
been described so far. Superficial spreading melanoma, most common in 30-50 year-old 
patients, spreads horizontally with an early flat appearance, and irregular pigmentation and 
margins; lentigo maligna melanoma is typically located on sun-exposed sites (head, neck 
and arms) and presents large (3-4 cm in diameter) and irregular lesions with a very slow 
growth over 5-20 years; nodular malignant melanoma develops from dark and uniformly 
coloured lesions, which may ulcerate and bleed, it lacks the radial growth phase and can 
result in a rapid invasion of the dermis. These three types account together for 
approximately 85% of all melanoma cases. Other less frequent forms include desmoplastic 
melanoma, with a highly variable clinical appearance, mucosal lentiginous melanoma and 
acral lentiginous melanoma, the most common type in dark-skinned populations (Africans 
and Hispanics). 
 
 
Fig. 1. Melanoma natural history. 
www.intechopen.com
 Familial Melanoma in Italy: A Review 
 
101 
Five proposed stages for melanoma development and corresponding molecular events 
involved in malignant melanoma pathogenesis. (MC1R: MelanoCortin 1 Receptor; 
CDKN2A: Cyclin-Dependent Kinase iNhibitor 2A; PTEN: Phosphate and TENsin homolog; 
CDK4: Cyclin Dependent Kinase 4; MLANA: MeLANin-A; TRPM1: Transient Receptor 
Potential cation channel sub-family M member 1; MMP2: Matrix MetalloProteinase 2).   
1.2 Melanoma epidemiology and etiology 
It was reported that melanoma incidence rose during the last century worldwide. In recent 
decades, the annual increase in incidence rate was reported to be in the order of 3-7% for fair 
skinned Caucasians (Armstrong & Kricker, 1994) and to vary among populations with age, 
gender (Jemal et al., 2001) and geographical area. Melanoma is the third more frequent 
cancer in 30-45 years age group, with a higher occurrence in female and in fair-skinned 
populations living in sunny areas. Some dermatologists questioned whether this rising in 
melanoma incidence could reflect a real increase of disease occurrence or if it could be 
ascribed to a more intensive surveillance. Undoubtedly, implementation of screening 
programs has allowed the early detection of a larger number of pigmented and potentially 
suspect skin lesions (Dennis, 1999), with a corresponding larger number of new cases per 
year, that could, at least in part, justify the overall incidence increase. Moreover, some 
initially unsuspected lesions can be correctly diagnosed as true malignant melanomas (the 
so called “incidental melanomas”) later on by histo-pathological analysis, because of 
persisting diagnostic limitations for very early lesions (Swerlick & Chen, 1997). Importantly, 
despite a higher incidence, melanoma mortality remains stable over the years. 
Italy is considered a low melanoma incidence country, with geographical variations 
according to a decreasing North-South gradient, as reported by the Italian Cancer Registries. 
Melanoma incidence rates in Italy were reported to be of 8.5 cases per 100,000 in male and 
10.2 case per 100,000 in female (Boi et al., 2003).  
1.2.1 Risk factors 
Melanoma epidemiology involves not only incidence and mortality rates, but also possible 
causal factors. Melanoma is characterized by a complex etiology, concerning both 
constitutional and environmental factors, that mostly in combination determine the 
likelihood of developing the disease. There is no question that sun exposure is the major 
environmental risk factor (Oliveria et al., 2006). Several data from epidemiological analysis 
on migration and geographical residence showed an increased risk in sunny areas, 
especially for individuals exposed during childhood and adolescence, both crucial ages for 
subsequent melanoma development (Autier et al., 1997; Robsahm & Tretli, 2001). 
Conflicting evidence, however, were reported to this end, since several studies did not 
confirm the role of childhood/adolescence as “critical time periods” (Kaskel et al., 2001; 
Pfahlberg et al., 2001). Intermittent sun exposure and sunburns, in particular, appear to be 
relevant factors as well (Gandini et al., 2005a).  
To date, limited data are available on melanoma risk factors in Mediterranean populations, 
one of the largest Italian collaborative case-control study investigated the role of different 
potential risk factors, comprising modalities of sun reaction and history of sunburns (Naldi 
et al., 2000). Moreover, an Italian research group recently reported a protective effect of the 
so-called Mediterranean diet on cutaneous melanoma onset (Fortes et al., 2008). 
On the other hand, several constitutional risk factors were shown to be involved in 
melanomagenesis. Phenotypic traits, including skin phototype and pigmentation (fair 
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complexion and sensitivity to sunburns), presence of freckles and light-coloured eyes are 
additional examples of host-related risk factors (Gandini et al., 2005b). Several evidence 
suggested that while the number of melanocytic nevi can represent a proper melanoma 
predictor, the presence of atypical nevi may assume an independent role (Bataille et al., 1998; 
Tucker et al., 1997). Thus, melanoma risk raises with nevus number and clinical atypia degree, 
with the highest risk for individuals presenting multiple atypical nevi (MacKie et al., 1993).  
1.2.2 Familial melanoma 
Probably, the most important and well documented host-related risk factor is familial 
history of melanoma, defined by the presence of two or more relatives affected by 
melanoma within a family branch. Familial melanoma accounts for approximately 5-10% of 
all melanoma cases and segregation analysis revealed an autosomal dominant mode of 
transmission. Moreover, likewise other inheritable cancer syndromes, familial melanoma is 
characterized by peculiar features (Kopf et al., 1986) including early age of onset, multiple 
primary melanomas and association with other cancers, namely pancreatic carcinoma in the 
so-called “Familial Melanoma/Pancreatic Cancer Syndrome” (Lynch et al., 2002). On the 
other hand, as for histological and clinical aspects, familial melanoma is indistinguishable 
from sporadic cases. Even though exposure to common environmental risk factors cannot be 
excluded, familial aggregation can be prevalently attributed to shared genetic factors and 
several melanoma-predisposing genes were identified so far. A crucial aspect of familial 
melanoma, as well as any cancer syndromes, is that what is inherited is a genetic 
predisposition, i.e. a greater risk, rather than the disease itself. The reason is that a mutated 
allele of a specific cancer-predisposing gene is constitutively present in every cell of the 
body (Knudson’s “first-hit”). Thus, individuals belonging to melanoma-prone families, once 
carriers of genetic predisposition, have a markedly higher risk to develop melanoma during 
their lifetime, compared to the general population. 
Aim of the present review is the description of the genetic basis of familial melanoma, the 
role of genetic counseling in its early diagnosis, the laboratory assessment of pathogenic 
gene mutations and an overview of the main studies and research investigations performed 
on familial melanoma in Italy.  
2. Genetic basis of familial melanoma 
During oncogenesis, both inherited and/or acquired genetic alterations take part in a 
multistep process that finally results in an invasive and metastatic neoplastic growth. 
Hereditary cancer syndromes, in particular, represent a model for the analysis of how 
germline mutations of specific genes can modulate cancer risk and hence influence the 
development of disease. 
Several genes involved in familial melanoma susceptibility were reported and recent 
advances in molecular genetics, including genome-wide association studies (GWAS), may 
identify additional melanoma-predisposing alleles in the future.  
2.1 High risk genes 
The identified melanoma susceptibility genes include rare high risk and more common, 
moderate/low risk genes. It is important to point out that there is not an absolute distinction, 
in terms of conferred risk, between these two categories, but most likely a continuous gradient 
of gene effects, leading to a variable (from strong to weak) melanoma risk.   
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2.1.1 CDKN2A     
The first real clues about the existence of a major melanoma susceptibility gene came from 
molecular cytogenetic evidence. Melanoma cell lines were found to have frequent deletions 
of the 9p21-p22 chromosome region and linkage with markers at 9p13-p22 was 
subsequently reported in several melanoma families. Some years later, a combination of 
tumour deletion and recombination mapping studies in melanoma families was used to 
further limit the position of a candidate gene that was then cloned, sequenced and 
recognized to be identical to a previously characterized cell cycle regulatory gene. This gene 
was variably called INK4A, CDK4I or MTS1, but designed by now as CDKN2A (for Cyclin-
Dependent Kinase iNhibitor 2A) by the Human Genome Organization Nomenclature 
Committee.   
CDKN2A is the most common high risk susceptibility gene identified to date in familial 
malignant melanoma. The CDKN2A locus possesses a rather unique genomic organization: 
it consists of two upstream exons, 1ǂ and 1ǃ, driven by different promoters, that are 
combined to the common exons 2 and 3 to produce two distinct proteins. The transcript for 
p16INK4A is initiated from the proximal promoter of exon 1ǂ that is joined to exons 2 and 3, 
while p14ARF transcript starts from the upstream promoter and is made of exon 1ǃ plus 
exons 2 and 3 read with a different frame (ARF stands for Alternative Reading Frame). Thus, 
the CDKN2A particular genome arrangement (Figure 2), likely arisen by gene duplication 
(Gil & Peters, 2006), and its alternative exon splicing allow to produce two totally distinct 
proteins from a shared coding sequence (Sherr, 2001). 
2.1.1.1 p16INK4A/p14ARF structure and function 
More in detail, p16INK4A (p16 for simplicity) belongs to the INK4 protein family, of four 
members with the capacity to inhibit cell cycle progression; p16 consists of 156 amino acidic 
residues, spatially organized into four ankirin repeats, which are structural motifs involved 
in a large number of protein-protein interactions. A single ankyrin repeat is composed by 
approximately 33 residues that fold into anti-parallel helix-loop-helix structures, linked by 
ǃ-hairpins (Zhang & Peng, 2000). All these four ankirin repeats are needed for the 
interaction of p16 with its target: p16 binds to CDK4/6 (Cyclin-Dependent Kinases) and 
inhibits the catalytic activity of cyclin D-CDK4/6 complexes, hence maintaining the 
oncosuppressor pRb in its hypo-phosphorilated state (Lukas et al., 1995), thus preventing 
G1/S transition. 
The p14ARF protein (p14 for simplicity), instead, is made up by 132 residues and there are 
no recognizable protein motifs in its structure. It can limit aberrant cell proliferation by 
binding to and blocking MDM2 and, thus, stabilizing p53 (Stott et al., 1998); increased 
intracellular levels of p53, in turn, mediate cell cycle arrest and apoptosis. Recent evidence, 
however, support additional roles of p14 in mediating p53-independent responses (Eymin et 
al., 2003). Although p16 and p14 act on distinct molecular pathways, it is important to point 
out that both are involved in tumour suppression, despite of species- and cell type-specific 
differences between the two; moreover, their functions show some overlap, due to 
functional interconnections between p53 and pRb pathways (Bates et al., 1998; Sherr & 
McCormick, 2002). 
Due to the wide role of CDKN2A in tumour suppression and together with the ubiquitous 
expression of both p16 and p14 oncosuppressors, one wonders why there is such a specific 
predisposition to melanoma, and not to other malignancies. This type of “tissue specificity 
of gene defects” is commonly found in the majority of hereditary tumour syndromes and a 
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possible explanation relies on how the same gene might possess entirely distinct functions, 
depending on its cell type specific expression. In the case of p16, in particular, the role of this 
protein in activating replicative senescence, an irreversible G1 arrest of still metabolically 
active cells (Campisi, 1997), has been well established. In human melanocytes, p16 is the 
master regulator of cell senescence (Sviderskaya et al., 2002) that has no other redundant or 
compensatory pathways in this particular cell type; this might explain why individuals and 
families with a germline CDKN2A mutation are prone to melanoma development, due to 
the specific impairment of melanocyte senescence, a crucial barrier against tumorigenesis. 
 
 
Fig. 2. Genomic organization of CDKN2A locus. 
Exons 1ǂ, 2 and 3 code for p16INK4A, able to bind CDK4 and block its activity, thus 
maintaining the pRb in a hypo-phosphorilated state and, hence, E2F transcriptional factors 
inactive. Exons 1ǃ, 2 and 3 are joined into the ǃ transcript, coding p14ARF, that inhibits the 
ubiquitin-ligase activity of MDM2, with a following p53 accumulation. Both, the pRb and 
the p53 pathways, finally result in G1 cell cycle arrest. 
2.1.1.2 CDKN2A and melanoma predisposition 
A variety of CDKN2A germline mutations have been identified to date in melanoma-prone 
families, while they are reported to be rare in the general population. The relative risk of 
melanoma development conferred by CDKN2A mutations in the general population was 
estimated by an international case-control study (Berwick et al., 2006). This study 
determined an overall relative risk of melanoma associated with CDKN2A mutations of 4.3, 
with considerable variations of this value, depending on the particular type of mutation.  
In order to better characterize mutations in this high-risk melanoma susceptibility gene, the 
International Melanoma Genetics Consortium (GenoMEL), comprising most familial 
melanoma research groups from North America, Europe, Australia and Middle East, 
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performed a large study on 446 families with at least three malignant melanoma patients, 
for a total of about two thousands enrolled patients (Goldstein et al., 2006). Overall, 41% of 
families had CKDN2A mutations, with differences in the mutation detection rates among 
several geographic areas. CDKN2A mutations targeting the p14 sequence only (i.e. localized 
mainly in exon 1ǃ) were much less common and present in only seven families, while 
mutations affecting the p16 sequence were detected in 178 families and were present in both 
exon 1ǂ and exon 2. Moreover, the 57 different p16 mutations included: missense mutations 
(65%), deletions (16%), insertions or duplications (7%), nonsense and splicing mutations 
(10%). Many of the most recurrent CDKN2A mutations were “founder mutations”, 
originated from a common ancestor and dating back 100 generations (Pollock et al., 1998). 
Moreover, a significantly younger median age at melanoma diagnosis was observed in 
mutated families than in families without mutations. Furthermore, the probability to detect 
a CDKN2A mutation was dependent on the number of melanoma cases within each family 
(Kefford et al., 1999). Interestingly, the presence of pancreatic cancer was confirmed to be 
associated with a higher CDKN2A mutation frequency. 
Finally, given a certain CDKN2A mutation, what is the risk of melanoma development in a 
mutation carrier? Again, a study by GenoMEL on 80 families with at least two melanoma 
cases in first-degree relatives, for a total of about 400 melanoma patients from Europe, 
Australia and United States, provided data on CDKN2A mutation penetrance (Bishop et al., 
2002). Overall, CDKN2A mutation penetrance was estimated to be 30% by age 50 and 67% 
by age 80, without significant modifications by gender or co-presence of p14 mutations. 
Importantly, also in this case the penetrance was reported to be strongly influenced by 
geographic areas and, hence, by environmental exposure: for instance, by age 80 the 
penetrance was 58% in Europe, 76% in the United States and 91% in Australia, also showing 
that penetrance varied with melanoma incidence rates among populations.     
2.1.1.3 CDKN2A and melanoma/pancreatic cancer syndrome 
Approximately 5-10% of pancreatic cancer (PC) cases are attributable to hereditary cancer 
syndromes (Habbe et al. 2006). Virtually all PCs have somatic inactivation of CDKN2A 
(Schutte et al., 1997), thus suggesting a critical relevance of this locus in PC pathogenesis 
and an association between PC and CDKN2A mutations was described. Several authors 
(Goldstein et al, 1995; Goldstein, 2004; Whelan et al., 1995) showed that PC was found in 
carriers within melanoma families harbouring CDKN2A mutations and a more recent study 
showed that individuals possessing the p16-Leiden mutation (a specific 19 base-pair 
deletion in exon 2) had an estimated cumulative risk of 17% to develop a PC with a mean 
age at diagnosis of 58 years (Vasen et al., 2000). In 2002, Lynch and co-workers analyzed 
eight families characterized by melanoma/PC association and presence of CDKN2A 
mutations, and they proposed the possibility of a new hereditary cancer syndrome, defined 
as “Familial Atypical Multiple Mole Melanoma-Pancreatic Carcinoma” (FAMMM-PC) 
syndrome (Lynch et al., 2002).    
At present, however, several questions remain, and the molecular mechanisms linking 
CDKN2A function and PC development need further investigations. Moreover, it is not yet 
clear which CDKN2A mutations are specifically associated with PC and why.  
2.1.2 CDK4 
The cyclin-dependent kinase CDK4 interacts with cyclin D and the resulting complexes 
catalyze the phosphorylation of target molecules that in turn promote the G1/S transition of 
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cell cycle. As previously discussed, CDK4 activity can be regulated by p16 and mutations in 
CDK4 gene could perturb the cell cycle control, when they disrupt the ability of CDK4 to 
bind p16. CDK4 mutations are very rare compared to CDKN2A (Goldstein et al., 2006): they 
occur in only 2% of families analyzed to date, with a pattern of inheritance and an age of 
tumour onset similar to that reported for CDKN2A mutations. 
The most recurrent mutations are localized in codon 24, replacing an arginine with a 
cysteine (Zuo et al., 1996) or a histidine (Soufir et al., 1998). These mutations, targeting the 
p16 binding site of CDK4, render the kinase resistant to p16 inhibition and thus convert 
CDK4 to a dominant oncogene, with only a single mutated allele required for tumorigenesis.   
2.2 Moderate/low risk and modifier genes 
2.2.1 More on hereditary genetic risk 
High-risk genes alone do not completely account for the heterogeneous genetic substrate 
underlying familial melanoma. Only a small fraction of melanoma-prone families, in fact, 
carries mutations in the highly penetrant loci described above. The remaining genetic risk 
could be due to high penetrance genes not yet identified or, more likely, to other less 
penetrant, lower risk genes. The so called “polygenic model” states that a large number of 
alleles, each conferring a small genotypic risk, combine additively or multiplicatively to 
confer a range of susceptibilities to the population (Houlston & Peto, 2004). Thus, the 
particular allelic pattern may influence the lifetime risk of an individual, but also 
expressivity and penetrance of high risk loci, acting as “modifier risk genes”. Within low 
penetrance inheritance, the polygenic component is significantly represented by Single 
Nucleotide Polymorphisms (SNPs) that characterize each susceptibility allele. These 
polymorphisms could directly regulate molecular pathways involved in tumorigenesis 
initiation and progression (i.e., metabolism dysfunctions, cell death, inflammation, immune 
response and angiogenesis) or could modulate the host response to environmental factors 
(DNA-damage repair after sun exposure). The relevance of these numerous low penetrance 
genes justifies the considerable efforts that were made in their identification, mainly 
performed by case-control studies on candidate genes and, more recently, by GWAS. So far, 
several moderate/low penetrance genes were described, but for most of them the clear 
contribution to cancer development was not yet exhaustively elucidated. Gene functions, 
redundancy in the cellular pathways and protein pleiotropism represent, in fact, the main 
complexities in the comprehension of this field (Caporaso, 2002). For familial melanoma, 
different moderate/low penetrance genes were reported to influence the lifetime risk of 
developing the disease. 
2.2.2 MC1R 
The MelanoCortin type-1 Receptor (MC1R) is a seven-pass transmembrane G-protein-
coupled receptor, specifically expressed on skin melanocytes. Functionally, MC1R is an 
upstream component of the intracellular pathway leading to melanin biosynthesis and skin 
pigmentation. The binding to its ligand ǂ-MSH (Melanocyte Stimulating Hormone) activates 
MC1R, with upregulation of intracellular cAMP levels that, in turn, modulate melanin 
production (Figure 3). Two melanin types are present in mammals: pheomelanin, a red-
yellow pigment, typical of the so-called RHC (Red Hair Colour) phenotype, and eumelanin, 
the darker pigment that confer olive complexion and brown/black hair. MC1R engagement 
can shift the intracellular pheomelanin/eumelanin balance, thus increasing the production 
of the latter and modulating skin sensitivity to sun exposure (Sturm et al., 2001). A 
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functional impairment in MC1R signalling alters the downstream pigmentation pathways, 
causing an accumulation of pheomelanin that, in turn, has reduced UV protective capacity 
and can produce cytotoxic and mutagenic metabolites (Sturm, 1998), accelerating 
melanocytic transformation. This functional impairment can result from different 
mechanisms: some variants fail in the stimulation of cAMP production (Beaumont et al., 
2007; Garcia-Borron et al., 2005), while others show MC1R reduced affinity for its ligand ǂ-
MSH (Ringholm et al., 2004) or there are even defects in desensitization and internalization 
of the MC1R receptor itself (Sanchez-Laorden et al., 2007).    
Given the role of MC1R on epidermal response to UV-induced damage, it is not surprising 
that the MC1R allelic state influences melanoma risk, by directly regulating skin 
pigmentation. MC1R locus is highly polymorphic in Caucasians (Savage et al., 2008) and 
over 100 variants have been identified so far. These include “R” alleles, found to be 
prevalently associated with light skin, red hair, freckles and sun sensitivity (termed RHC 
phenotype), all known melanoma risk factors, and “r” alleles, with a weaker or absent 
association with the RHC phenotype. The molecular basis discriminating between R and r 
alleles apparently resides in the complete (R) or partial (r) loss of the receptor signalling 
ability. Recently, it was demonstrated that melanocytes harbouring R alleles possessed 
markedly reduced surface expression and/or impaired G-protein coupling of the 
corresponding receptor (Newton et al., 2007). 
It is important to underline that MC1R variants have also a different functional causative 
role on melanoma development and several studies showed that R variants were more 
strongly responsible for melanoma risk (Kanetsky et al., 2006). In a very recent meta-
analysis, the estimated summary relative risk for R and r alleles were found to be of 2.44 and 
1.29, respectively, although both estimates were associated with evidence of substantial 
heterogeneity across studies (Williams et al., 2010). In Italy, some R alleles, such as R151C 
and R160W, were reported to confer an attributable risk of 7.48 and 4.54, respectively 
(Raimondi et al., 2008).   
By all means, correlations between MC1R allelic status, skin pigmentation features and 
melanoma onset are more complex. Some “R” variants could not be associated with a RHC 
phenotype; moreover, MC1R might influence melanoma development by acting on different 
molecular pathways that are pigmentation-independent such as a MC1R-induced 
upregulation of p38 MAPK in melanocytes, likely occurring via cAMP (Newton et al., 2007). 
Potential downstream outcomes of p38 activation include histone H3 phosphorylation with 
subsequent chromatin remodelling and altered gene regulation, relevant for non-
pigmentary pathways including cell cycle regulation, differentiation, and apoptosis. 
A variety of studies have reported that MC1R variants can markedly modify the penetrance 
of CDKN2A locus (Box et al., 2001; Fargnoli et al., 2010; Goldstein et al., 2005, 2007). To this 
end, a recent study performed by GenoMEL (Demenais et al., 2010) investigated the 
associations among host phenotype, MC1R variants and melanoma risk in CDKN2A 
mutation carriers. The analysis, performed on 815 mutation carriers from Europe, North 
America and Australia, showed interesting results: both non-RHC and RHC variants were 
associated with increased melanoma risk, that rose threefold in presence of at least one 
MC1R variant; moreover, the risk was higher in presence of RHC variants and a higher 
number of MC1R variants. Interestingly, the MC1R-associated risk seemed even greater 
when CDKN2A mutations affected p16 only, than when they involved both p16 and p14. In 
addition, hair colour and a high number of nevi are significantly associated with increased 
melanoma risk; in presence of this host phenotype, the increase in melanoma risk with 
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anyone of the four more frequent MC1R variants (V60L, V92M, R151C and R160W) 
remained statistically significant. In conclusion, melanoma risk in CDKN2A mutation 
carriers is modified by type and number of concurrent MC1R variants, thus confirming the 
role of MC1R as a risk modifier gene. 
 
 
Fig. 3. MSH-MC1R signalling pathway. 
The binding of the ǂ-MSH ligand activates G-coupled MC1R, with subsequent cAMP level 
increase, through the catalytic activity of Adenilate Cyclase (AC). The intracellular cAMP 
accumulation up-regulates the expression of key genes: MITF plays a pivotal role in 
mediating transcriptional control of numerous other genes. Activated pigmentary genes 
include SLC45A2, TYR and DTC, that all modulate melanin synthesis and skin colour, and 
OCA2, involved in the regulation of the facultative pigmentation. Other MC1R-up-regulated 
non-pigmentary genes comprise c-Fos, a well-known transcription factor influencing DNA-
repair, cell cycle regulation and apoptosis, and p38 MAP kinase (Newton et al., 2007).  
2.2.3 Additional pigmentation genes 
Human pigmentation is a polygenic trait influenced by a plethora of different genetic 
determinants. In addition to MC1R, several other pigmentation genes were described to be 
associated with melanoma risk. A large-scale association study investigated different loci 
able to influence hair, eye and skin colour (Gudbjartson et al., 2008). Variants at three of 
these loci showed significant association with melanoma. In particular, the strongest 
association was found with ASIP locus (on chromosome 20q11.22), coding for Agouti 
SIgnalling Protein, a second ligand of MC1R and an antagonist of ǂ-MSH. In principle, 
mutation in ASIP could mimic a loss-of-function of MC1R; to date, no variants have been 
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identified in the coding regions of ASIP. The other two associated loci were TYR and TYRP1, 
involved in pheomelanin/eumelanin biosynthesis. 
2.2.4 Other genes  
A GWAS carried out by the GenoMEL (Bishop et al., 2009), identified the 
MethylThioAdenosine Phosphorylase (MTAP) gene, adiacent to CDKN2A on 9p21, coding 
the first enzyme of the methionine salvage pathway and having a documented tumour-
suppressor activity, as a melanoma-associated locus. MTAP variants were found to be 
strongly associated with a high melanocytic nevus number (Falchi et al., 2009), one of the 
strongest known melanoma risk factor. 
Epidermal Growth Factor (EGF) gene was also considered a reasonable risk candidate: a 
specific SNP, located upstream of the initiation codon of pre-pro-EGF, is more frequent in 
melanoma patients than in unaffected controls and it is reported to confer a 2.7 relative risk 
of disease development (Shahbazi et al., 2002). 
Glutathione S-Transferases (GSTs) are a family of isoenzymes largely involved in metabolic 
processes. Interestingly, GST genes are candidates for modulating CDKN2A penetrance. GST 
genes Mu1 (GSTM1) and Theta 1 (GSTT1) are specifically expressed in the skin to detoxify 
products from oxidative stress reactions caused by UV irradiation. A homozygous deletion of 
GSTM1 (GSTM1 null) is present in about 50% of Caucasians, while about 20% of them carry a 
homozygous deletion of GSTT1 (GSTT1 null). In particular, combined deletions of both genes 
were found associated with increased UV sensitivity and UV-inducible skin cancers, and null 
gene variants were also proposed as melanoma risk factors (Mössner et al., 2007).   
Another locus governing metabolic processes and involved in melanoma susceptibility codes 
for CYtochrome P450 Debrisoquine Hydroxylase (CYP2D6). Different inactivating 
polymorphisms were found to be more recurrent in melanoma patients, who were frequently 
homozygous for these non-functional alleles, than in controls (Strange et al., 1999).  
Additionally, it was shown that a SNP in the MDM2 gene, the SNP309 (T>G variation) was 
linked to the tumour onset and outcome. However, discordant results were reported on the 
effect of this SNP on age at diagnosis of cutaneous melanoma in Caucasian female 
population and no associations were found among SNP309, melanoma risk, age at diagnosis 
and presence of metastasis in the Italian population, although SNP309 was significantly 
associated with tumour Breslow thickness (Capasso et al., 2010). 
It was proposed that the Vitamin D Receptor (VDR) gene might play a role in melanoma 
development as well, since its interaction with the calcitriol ligand results in 
antiproliferative and pro-differentiation signals on melanocytes. Rare VDR alleles were 
found more commonly in melanoma cases than controls, although conflicting evidence were 
also reported (Barroso et al., 2008; Hutchinson et al., 2000). 
All these evidence stress the fact that melanoma, being a multifactorial disease, is 
characterized by a heterogeneous genetic background and further investigations on 
melanoma-predisposing genes are necessary to gain new insights into this overwhelming 
wealth of information and, in turn, to the comprehension of melanoma pathogenesis.  
3. Genetic counseling and testing for familial melanoma 
3.1 Genetic screening: how and why 
In general terms, screening is a systematic attempt to identify, among apparently healthy 
individuals, those at higher risk for a specific disease, to finally inform them about 
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preventive protocols. The aim of cancer screening can be either to identify precancerous 
lesions, whose treatment will be truly preventive (primary prevention), or to diagnose 
cancer at an earlier stage and treat the tumour more efficiently (secondary prevention).  
In the case of cancer syndromes, the existence of inherited alterations in tumour-
predisposing genes can be detected by a genetic test, which is a DNA analysis to determine 
the presence of a mutation that could be responsible for the development of the disease. 
Thus, for hereditary cancers, genetic testing is used to predict the risk of a future health 
impairment (Tsao & Niendorf, 2004). 
The application of each genetic test in the clinical practice should be considered in 
conjunction with a formal and qualified genetic counseling setting, in which an inter-
disciplinary team of specialists, such as geneticists, clinicians and psychologists, provides a 
comprehensive consultation service, with the purpose to elicit the patient’s personal and 
familial health history, to assess genetic risk, to discuss with patients and families about 
benefits, limitations, interpretations and possible implications of genetic testing and 
diagnosis, to assess the need of a psychological support, and to include individuals in 
appropriate screening programs (Niendorf & Tsao, 2006). 
The methodology of genetic counseling implies, firstly, the collection of the family 
pedigree, which is a genealogic tree used to analyze the mendelian inheritance of a certain 
trait, such as the presence of a mutation in a cancer-predisposing gene. It is particularly 
important to include the widest amount of information about the number and type of 
cancer-affected patients, their age at onset, the presence of multiple cancers in the same 
individual and the occurrence of cancers known to be associated with the syndrome of 
interest (as in the association of pancreatic cancer with familial melanoma). All the 
collected data allow prediction of the so called “theoretical risk”, given as the product 
between the probability to have inherited a mutation in a susceptibility gene and the 
mutation penetrance at a given age. In general, the presence of two or more affected first-
degree relatives, an early age at onset and a personal history of multiple primary cancers 
are features that strongly suggest an inheritable genetic cancer predisposition. In such a 
case, a genetic test for the molecular characterization of a given cancer-predisposing gene 
can be offered to the proband, the first affected member of the family enrolled for the 
screening, in association with an informed consent about the predictive power and the 
limits of the test.   
3.2 Genetic test for CDKN2A 
The aim of genetic testing for CDKN2A is to identify which family members are mutation-
carriers, in order to target these higher risk individuals to more intensive cancer prevention 
and surveillance. 
In a recent study, the predictive value of personal and familial history of melanoma/ 
pancreatic cancer was assessed for the identification of individuals at increased probability to 
harbour a CDKN2A mutation (Leachman et al., 2009). The study demonstrated that in higher 
melanoma incidence areas, individuals with multiple primary melanomas and/or families 
with at least one invasive melanoma and two or more melanoma and/or pancreatic cancer 
cases among first- or second-degree relatives in the same familial side represented appropriate 
candidates for genetic evaluation. On the other hand, in geographic areas with lower 
melanoma incidence rates, two melanoma and/or pancreatic cancer cases within a family 
could be sufficient and appropriate for a genetic investigation.  
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When performed, genetic testing is based on the mutational analysis of CDKN2A locus: 
genomic DNA, extracted from Peripheral Blood Mononuclear Cells (PBMCs) of the patient, 
is subjected to sequencing techniques to analyse the whole gene sequence, including exonic 
and intronic regions, splicing junctions and 3’/5’UTR. A written informed consent has to be 
obtained for all tested patients under local ethic committee-approved protocols. 
The interpretation of the possible results of a genetic test represents one of the most delicate 
issues in this context (Udayakumar & Tsao, 2009) and must be done by specialists with 
genetics expertise. When a specific mutation is detected, the patient might develop a 
melanoma during life, because of his increased risk, compared to the general population, due 
to the occurrence of the inherited mutation. The detected mutation provides a sort of familial 
genetic signature and other family members could be tested for it (specific test). When the 
mutation occurs within the family, but it is absent in a given member (non-carrier), the result 
of the specific test is negative. However, even in presence of a negative specific test, an 
increased risk for family members still persists, due to the possible co-inheritance of other 
shared genetic, risk-modifier factors. On the other hand, and most often, when no mutation is 
detected in a melanoma-prone family, the test does not provide any new information; in this 
case, other types of CDKN2A mutations or other melanoma-predisposing genes could be 
involved in determining that specific pedigree, hampering the possibility to rule out 
hereditary melanoma. Of course, families comprising individuals with uninformative tests are 
considered at increased risk, irrespective of their DNA status. An uninformative test is also 
obtained when a genetic alteration with unknown functional significance (the so called 
“Unclassified Variants”, UVs) is identified, as later discussed in more detail.  
For all these reasons, it is generally recommended that members of melanoma families 
should be invited to participate in screening and cancer prevention programs, regardless of 
their CDKN2A mutational status (Hansson, 2008; Kefford et al., 1999). Primary prevention 
measures mainly include education for sun protection and routine skin self-examinations, 
while secondary prevention is focused on monitoring pigmented skin lesions, that could be 
considered as melanoma precursors, since early detection and surgical excision are the only 
powerful means presently available to improve melanoma prognosis.  
Undoubtedly, controversies on genetic tests for melanoma still exist (Kefford et al., 2002; 
Kefford & Mann, 2003), but the clinical utility of CDKN2A testing continues to improve and 
its potential benefits have been already established. 
3.3 Clinical counseling in Italy 
The variable melanoma incidence and CDKN2A mutation penetrance among countries 
render unfeasible the definition of international guidelines to regulate the access to genetic 
testing for CDKN2A, insomuch as specific selection criteria must be applied on a national 
scale. In Italy, one of the first countries where genetic testing for familial melanoma was 
offered in medical or genetics services, the Italian Society of Human Genetics (SIGU) 
outlined recommendations on genetic counseling and testing for familial melanoma, 
suggesting to offer genetic test for CDKN2A to those families with at least two first-degree 
affected members. A recent cooperative study, among 9 Italian centres, quantified the 
frequency of CDKN2A mutations in melanoma-prone families, in line with the SIGU 
eligibility criteria for clinical counseling, as summarized in Figure 4 (Bruno et al., 2009). This 
analysis, of 208 Italian families that met the SIGU criteria and underwent genetic testing, 
reported that 33% of the families overall carried CDKN2A mutations. More in detail, the 
results showed that CDKN2A mutation frequency rose with the number of affected 
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members in the family, that the median age at diagnosis was significantly different in 
individuals from CDKN2A-mutated families (42 years), compared to patients from families 
without  mutations (49 years), and that the CDKN2A mutation frequency increased with the 
number of patients presenting multiple primary melanomas within the family. In particular, 
families with two cases accounted for 71% of the entire sample and for 52% of the families 
harbouring CDKN2A mutations. These findings suggested that if stricter selection criteria 
for genetic test were applied in Italy (such as the presence of at least three affected 
members), a significant subset of CDKN2A mutated families would not be identified, a 
result that outlines how the definition of selection criteria to access to genetic testing should 
depend upon the particular geographic area of interest. 
 
 
Fig. 4. Italian Society for Human Genetics (SIGU) recommendations for clinical genetic 
counseling and testing for familial melanoma (Bruno et al., 2009, with modifications). 
www.intechopen.com
 Familial Melanoma in Italy: A Review 
 
113 
4. The problem of CDKN2A unclassified variants 
As previously anticipated, a possible outcome of genetic testing for CDKN2A can be the 
identification of an alteration with undetermined pathogenetic significance, that is an 
Unclassified Variant (UV), a result that can complicate rather than improve cancer risk 
assessment. In this case, a change in the nucleotide sequence is found, but there is not enough 
information to decide whether it affects or not the function of the gene product and, thus, 
cancer predisposition. UVs are mainly represented by non-synonymous changes in a given 
protein position, also called “missense variants”. Over 150 different UVs of CDKN2A, mostly 
targeting p16, were reported worldwide (Goldstein et al., 2004, 2006). The main features of 
these UVs were grouped together and are now also available on the Leiden Open Variation 
Database (LOVD; http://chromium.liacs.nl/lovd2/home.php?select_db=CDKN2A). 
Obviously, an uninformative result can be a source of anxiety for individuals and their 
offspring because they will not be able to use this information for clinical purposes. In 
addition, all first-degree relatives, including non carriers, are considered at risk as long as 
the contribution of the variant to disease cannot be assessed, resulting in frequently 
unnecessary psychological stress and lifelong screening. The distinction between a true 
pathogenic mutation and a benign variant represents an essential prerequisite to univocally 
distinguish individuals at higher risk and, consequently, to enroll them in prevention 
protocols. In the last few years, a growing number of sequence changes of undetermined 
clinical significance was reported, and this issue received the attention of a large number of 
investigators. Recently, the International Agency for Research on Cancer (IARC; the cancer 
research branch of the World Health Organization) convened a Working Group on UVs  in 
high-risk cancer susceptibility genes, CDKN2A included. The Group comprised 
investigators of different specialties with the aim to establish a standard approach to UV 
evaluation. Discussions and specific recommendations of the Working Group were reported 
in a series of articles published in the November, 2008 special issue of Human Mutation 
(Tatvigian et al., 2008a). 
Currently, there is a general agreement for UVs classification on the basis of a 
multicomponent model, integrating direct and indirect evidence, including genetic, 
bioinformatic and experimental data, thus providing the highest degree of accuracy in UVs 
assessment. 
4.1 Direct evidence of pathogenicity 
Various lines of evidence were proposed to address UV evaluation (Goldgar et al., 2004, 
2008). Some types of evidence determine a more direct association between presence of the 
variant and cancer development. The most straightforward genetic evidence is the co-
segregation of a given variant with the disease in pedigrees. It offers the advantage to 
depend only on the availability of DNA samples from several individuals belonging to 
families with the variant, although its power is limited by the number of informative 
meiosis, very low in small pedigrees, and of affected members in the family. A second direct 
evidence is the evaluation of the variant frequency in case-control studies, particularly 
suitable for common genetic variants. For most UVs, however, their rare frequency would 
require prohibitively wide sample sizes to demonstrate its pathogenicity. Practically, this 
method is mainly used to rapidly screen out potentially neutral variants. 
An additional evidence relies on co-occurrence analysis: in principle, if there is a known 
pathogenic mutation in a melanoma family, its presence will decrease the probability that a 
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given variant, found in association with that mutation, could be pathogenic as well. In other 
terms, a probably pathogenic variant will not be found in co-occurrence with a bona-fide 
mutation.  
In the case of CDKN2A, the frequency of rare variants, the low number of carriers within 
melanoma families and the small pedigrees make difficult the application of all the above 
mentioned evidences. 
4.2 Indirect evidence of pathogenicity: in silico analysis 
Recently, computational approaches, predicting potential effects of a missense variant on 
protein structure/function and activity, were developed and widely used to support the 
classification of UVs (Tavtigian, 2008b). Different computational tools are based on the 
pairwise comparison of the physico-chemical characteristics or evolutionary substitution 
frequencies between the wild-type and variant amino acid. The basic principle is that in 
almost all proteins some amino acid positions, critically relevant for protein function, are 
highly philogenetically conserved, and in general disease-associated variants are 
preferentially localized in these positions. Thus, the evolutionary conservation of the amino 
acidic position, at which the variant occurs, provides an indication of its putative 
pathogenicity. In addition to the conservation degree, the comparison of the physico-
chemical characteristics between any wild-type and variant amino acid position is taken into 
account, in order to evaluate the biochemical severity of the substitutions. Additional tools, 
based on similar theoretical assumptions, operate in Protein Multiple Sequence Alignments 
(PMSAs) across different species. Likewise, missense substitutions falling at gene positions 
that are evolutionary constrained are more likely predicted to be pathogenic. 
Known examples of methods based on evolutionary fitness and/or on biochemical 
parameters are represented by PAM 250 and BLOSUM 62. They are amino acid substitution 
scoring matrices derived from the frequencies with which the 20 amino acids are observed 
substituting each other in PMSAs of related proteins (Henikoff & Henikoff, 1992); they 
assign to each variant a different score value, depending on its substitution frequency, that 
eventually defines the likelihood to be deleterious, rather than neutral. 
Another missense substitution analysis algorithm is the Align-GVGD, based on the 
Grantham difference, that describes the difference in side-chain atomic composition, 
polarity and volume between any two amino acids (Grantham, 1974). Again, a score is 
attributed to the variant, according to the “conservative”, “non-conservative”, or “radical” 
substitution features. 
More complex algorithms consider also protein structural properties, generally available 
when the three-dimensional crystal protein structure has been solved. The structural 
features provide information about the possible location of the variant into binding sites or 
enzymatic active sites, secondary structural motifs (helices, sheets, loops, etc.) or about its 
solvent accessibility. In these terms, an amino acid substitution that presumably perturbs or 
disrupts such structural conditions is predicted to be deleterious for the protein function. 
Example of algorithms, based on a combination of biochemical parameters, PMSAs and 
structural features, include PMut (Ferrer-Costa et al., 2005), SIFT (Ng & Henikoff, 2003) and 
PolyPhen (Sunyaev et al., 2001). 
Due to their ability to analyze the expected effects of each individual variant, they were 
applied to the analysis of UVs of different cancer-predisposing genes, including CDKN2A 
(Chan et al., 2007). A recent study on a series of CDKN2A missense variants, however, 
showed potential limits of these approaches: widely conflicting results, in fact, were 
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obtained, with several specific variants, that were paradoxically predicted to be benign or 
pathogenic, depending on the software used (Kannengiesser et al., 2009). 
Undoubtedly, in silico approaches provide an excellent support for UVs classification, but 
their accuracy is apparently limited by the available evolutionary, mutational or structural 
databases and, in some cases, by intrinsic limitations of each individual method. Therefore, 
in silico analysis represents an ancillary strategy for the evaluation of UV pathogenicity, but 
it needs to be validated and complemented by additional, stronger evidence. 
4.3 Indirect evidence of pathogenicity: Functional analysis 
Indirect UV evaluation can be also performed by using laboratory tests that can measure the 
effects of a variant on the activity of the gene product (Couch et al., 2008; Olilla et al., 2008). 
The rationale for the use of functional assays relies on the fact that the detection of a 
decrease in activity of a tumour suppressor gene, due to the constitutive presence of a 
variant in its sequence, likely results in an increased cancer predisposition. Thus, functional 
assays able to quantify a reduced or altered protein function can be employed to potentially 
predict the outcome of the UV on protein activity and function. 
A powerful assay must be designed according to the functional properties of the encoded 
protein and hence each single cancer-predisposing gene requires the development of a set of 
specific tests.  
A variety of p16 missense variants were investigated by functional analysis (Kannengiesser 
et al., 2009; McKenzie et al., 2010; Ruas et al., 1999), since two main p16 functions can be 
easily measured in vitro: the CDK4/6 binding capacity and the p16 ability to arrest cell-
cycle. In particular, the advantage of using cell growth inhibition assays is that they evaluate 
a phenotype directly involved in tumorigenesis. Other functional tests developed for p16 are 
discussed in the following paragraph. 
Undoubtedly, several unsolved issues on the applicability of functional tests still remain. 
Firstly, the results obtained by various assays often disclose a relevant discordance, with the 
same variant showing a different behaviour, depending on the assay used. Approximately, 
one-half of the variants tested so far in literature possess normal CDK4/6 binding, but fail to 
trigger cell-cycle arrest. This indicates that a single assay is not sufficient to draw definitive 
conclusions, and multiple assays must be performed. To this end, a general consensus on 
the definition of the most suitable panel of assays to be used is still lacking. An additional 
complication for interpretation of test results relies on the fact that the variants show a 
continuum of impaired activity, ranging from UVs similar to the wild-type function to UVs 
with a complete loss-of-function. It is therefore necessary to establish threshold and cut-off 
values, for eventually distinguishing UVs with wild-type, intermediate or loss-of-function 
behaviours. Again, a general consensus on the degree of functional loss, which is required to 
classify a UV as pathogenic, is still missing. Nevertheless, there are no doubts that functional 
tests can provide significant information about the in vitro activity of an UV. 
4.3.1 Functional approach for a CDKN2A coding UV  
Recently, an exhaustive analysis on a p16 missense variant, as an example on the use of 
functional methods, was performed by our group (Scaini et al., 2009). The Gly23Asp (G23D) 
was identified in a family with three melanoma cases, even if only one of the two tested 
patients was a carrier; the same variant was previously reported in a French and in another 
Italian melanoma family. The aa protein position 23 falls within the ankyrin consensus 
sequence and other variants at codon 23 were reported, with different evidence indicating 
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some involvement in melanoma predisposition. Co-segregation of G23D with the disease 
was observed only in one of these three families, thus rendering this analysis to be not 
conclusive for the assessment of the variant pathogenicity. The presence of phenocopies, 
furthermore, might be likely due to the relevant role played by low penetrance genes, acting 
together with environmental factors within a family. Hence, the application of indirect lines 
of evidence, namely functional assays measuring key cellular p16 functions, was 
particularly useful for this variant classification. The protein ability to arrest cell cycle was 
evaluated by i) proliferation curves, showing the trend of cell growth in time, ii) colony 
efficiency assays, testing colony formation capacity when cells were seeded at low density, 
and iii) flow cytometric analysis, indicating a decreased percentage of G1-arrested cells, 
compared to p16-wild-type ones. Additionally, immunoprecipitation and mammalian two-
hybrid binding assays were employed to measure p16 ability to bind CDK4, while pRb 
phosphorilation was analysed by Western blotting. Furthermore, we confirmed previous 
evidence that some p16 deleterious variants show an altered cellular localization by 
immunostaining followed by fluorescence microscopy, forming both cytoplasmic and 
nuclear aggregates, possibly due to an incorrect folding of the mutant protein during post-
translational processing. The results obtained from all these functional tests, summarized in 
Figure 5, clearly showed an important impairment in G23D function, compared to p16 wild-
type. The experimental results were also found to agree with in silico predictions, thus 
supplying sufficient evidence to classify the variant as a “loss-of-function” mutation, which 
most likely predisposes carriers to melanoma development. 
4.3.2 Beyond missense variants: CDKN2A non-coding UVs  
Together with missense UVs, germline polymorphisms outside the coding regions of 
CDKN2A (i.e., promoter, splicing sites, 5’UTR and 3’UTR) were also detected (Hayward, 
2000). The first defined pathogenic mutation was the 5’UTR -34G>T transversion, which 
gives rise to an alternative translation initiating codon with a decreased usage of the wild-
type AUG, likely derived from a common founder in the United Kingdom (Liu et al., 1999). 
Two extensive studies screened more than 1kb of the p16 untranslated and promoter 
regions in search of mutations in English, Italian, American (Harland et al., 2000) and 
Australian families (Pollock et al., 2001); polymorphisms at positions -33, -191, -493, and -
735, as well as three novel variants at positions -252, -347, and -981 were  identified. 
However, these novel variants did not segregate with disease and were, thus, classified as 
rare polymorphisms. Rare polymorphisms or variants at the CDKN2A 5’UTR are currently 
defined as UVs after determining their frequency in control subjects and following co-
segregation analysis, when possible. While several functional tests for determining the 
pathogenicity of missense germline mutations in the coding regions were developed, there 
are no studies addressing the possible impact of promoter/5’UTR variants on p16 
transcription/translation, except for a single publication by an Italian group (Bisio et al., 
2010). Reporter assays were developed to study a panel of p16 5’UTR variants, recently 
identified in a hospital-based series of melanoma cases selected within an ongoing case-
control study from an Italian population. Polysomal profiling was also applied as a means to 
determine the relative impact of the 5’UTR variants on mRNA translation efficiency in 
heterozygous patient cells. Overall, the results provide tools to assess the functional 
significance of non-coding 5’UTR mutations and strongly suggest that the -21C>T non-
coding variant can be of clinical significance for melanoma predisposition due to its 
negative impact on the post-transcriptional dynamics of p16 mRNA. 
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Fig. 5. Functional analysis of the G23D missense variant (Scaini et al., 2009). 
(A) Pedigree of the Italian family harbouring the variant. Mutational analysis of the first 
proband (indicated by arrow) was uninformative, while the patient marked with asterisk 
and her father carried the variant. (B) Proliferation curve and (C) Colony efficiency assays, 
showing the aberrant cell growth of p1623Asp transfected cells. (D) Impressive reduction in 
CDK4 binding of the variant, compared to wild-type p16. (E) Analysis of pRb 
phosphorilation status showed a variant-associated accumulation of hyper-phosphorilated 
pRb. (F) Mislocalization analysis revealed presence of cytoplasmic and/or nuclear p1623Asp 
aggregates. All functional tests were performed in U2-OS or NM-39 cell lines. 
5. Mutational analysis of melanoma-predisposing genes in Italy 
As previously discussed, Italy is considered a low melanoma incidence country and Italian 
melanoma-prone families are generally characterized by a small number of cases (mostly 
two affected relatives within the same family). 
The estimated cumulative risk of developing melanoma over a lifetime in the Italian 
population is 0.5% (Balzi et al., 1997), unlike in the United States, Australia, and New 
Zealand, where the risks are 2.0% (Jemal et al., 2008), 3.3% (Holland et al., 1999), and 5.7% 
(Jones et al., 1999), respectively.    
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Because of this low melanoma incidence, a familial clustering in a Mediterranean country 
like Italy is particularly indicative of an inherited predisposition, since it seems very 
unlikely that such a familial aggregation could be due to chance alone. So, investigations 
addressing the involvement of this genetic component and the characterization of 
melanoma-associated gene alterations represent a relevant aspect of familial melanoma 
research in Italy.         
Recently, a comprehensive study, reporting data on CDKN2A/CDK4 mutational analysis, 
was published (Bruno et al., 2009; see section 3.3). The power of this study relies on some 
significant characteristics: i) it merges melanoma families and patients recruited by nine 
different centres spread from Northern to Southern Italy, all enrolled under the same 
eligibility criteria; ii) it quantifies mutation frequency values on a national scale; iii) it 
defines how mutation frequencies relates to other familial melanoma features, including the 
number of affected members in the family, the age at onset, and the presence of multiple 
melanomas. This study estimated a CDKN2A mutation rate of 33% overall, but single 
studies on families from different Italian regions reported variable mutation frequencies, 
with high values (>35%) for Liguria (Ghiorzo et al., 1999; Mantelli et al., 2002) and low 
values (7.3%) for Emilia Romagna and Marche (Landi et al., 2004). Moreover, the mutation 
frequency in melanoma families is approximately 17-22% for Lazio and Toscana in Central 
Italy (Binni et al., 2010; Gensini et al., 2007). Importantly, the frequency was found to be 
higher in regions with founder mutations (i.e. Liguria and Toscana, as later discussed). 
Further data on the genetics of familial melanoma in Italy come from a variety of different 
studies, heterogeneous in methodology and performed on narrow and localized regions. For 
this reason, each study adds relative results that need to be merged together for a better 
description of the mutational spectrum of familial melanoma in Italy. 
5.1 Italian studies on high penetrance melanoma genes 
Different CDKN2A germline mutations have been identified in Italy in the last two decades. 
As reported worldwide in other mutational studies, missense mutations are the 
predominant part of CDKN2A alterations and are scattered along its entire coding region. 
Nonsense mutations, splicing/intronic and regulatory mutations, as well as 
insertions/deletions, have been described with a much lower prevalence. 
5.1.1 Founder mutations  
While some mutations were observed only once, others were repeatedly found among 
families. The most recurrent CDKN2A missense mutation, in Italy and worldwide, is the 
Gly101Trp (G101W), identified in various families from different countries and particularly 
prevalent in French and Italian populations. Given its high frequency, the G101W was 
largely investigated, and its genetic origin was assessed using several families from Italy, 
France and United States (Ciotti et al., 2000). The haplotype analysis, carried out by means 
of eight polymorphic markers spanning the CDKN2A locus, revealed no evidence for 
mutational heterogeneity and suggested that the genotyped families derived from a single 
ancestral haplotype on which the mutation firstly occurred. The authors finally stated that 
although it was not possible to unequivocally determine the precise geographic location 
where the mutation arose and how it spread around the world, it is likely that the mutation 
originated in South-western Europe. Subsequently, the common genetic origin of the 
G101W was confirmed by a French study (Auroy et al., 2001).  Being a so common mutation, 
it gained the attention of other researchers and was also functionally characterized. 
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Interestingly, although the G101W showed some residual binding to CDK4/6 (McKenzie et 
al., 2010; Parry & Gordon, 1996), it was found to be clearly impaired in the ability to block 
cell cycle progression (Kannengiesser et al., 2009). These singular results obtained for the 
G101W emblematically represent the case of a mutation having discordant functional 
behaviours, on the basis of the particular assay used, as discussed before. 
Another frequent founder mutation identified in Italy was the Glu27X (E27X) mutation 
(Ghiorzo et al., 2006). In particular the E27X, co-segregating with the disease, was found in 
patients living in, or originally from, a very small area on the North border of Liguria, in 
North-western Italy. The mutation, located in exon 1ǂ, determines a premature termination 
codon with a mutant RNA transcript containing only 27 codifying codons, which results in 
the synthesis of a truncated protein, and possibly in p16 haploinsufficiency. Interestingly, 
the E27X is the first stop codon CDKN2A founder mutation detected in melanoma families 
presenting also PC and neuroblastoma, while PC was preferentially reported in association 
with exon 2 mutations, impairing both p16 and p14.  
In a study addressing the frequency and spectrum of CDKN2A/CDK4 mutations in families 
from central Italy, a third Italian founder mutation, the Gly23Ser (G23S), was detected 
(Gensini et al., 2007). Again, the haplotype analysis revealed a single common origin for the 
G23S and several lines of evidence (co-segregation with the disease and case-control studies) 
suggested its pathogenicity and its involvement in melanoma predisposition.  
Taken together, these data show that the major burden of CDKN2A-associated familial 
melanoma in Italy can be attributed to a limited number of mutations which spread 
nationwide through founder effects. 
5.1.2 Other missense mutations  
More than ten years ago, when evidence for CDKN2A involvement in familial melanoma 
seemed still controversial, a European collaborative work headed by Fargnoli and coll (1998) 
was performed, to better establish the role of CDKN2A in melanoma predisposition. Four 
independent missense mutations in exon 1ǂ and exon 2 were detected in four of ten tested 
families, while no mutations in exon 1ǃ were found. The Gly23Asp (G23D) and the Asn71Ile 
(N71I) variants, showing co-segregation with the disease, were both located within 
consensus amino acid residues of the ankyrin repeats, crucially involved in p16 function. 
The Arg24Pro (R24P) and the Pro114Leu (P114L) were located in exon 1ǂ and exon 2, 
respectively, and for the former a defective binding with CDK4 was previously reported 
(Harland et al., 1997).  
Another Italian CDKN2A mutational analysis revealed a novel mutation, the Pro48Thr 
(P48T), showing co-segregation with the disease (Della Torre et al., 2001). The proband 
carrying the P48T mutation was a woman who developed 4 primary melanomas before age 
56; moreover, she belonged to a large family, presenting single and multiple melanomas, 
oral and colon cancers, bone tumours and other additional cancer types. In the same study 
the P48T was functionally characterized and it was indistinguishable from wild-type p16 in 
its ability to interact with CDK4/6, but it had a reduced capacity to inhibit cell growth with 
a defect in G1/S arrest clearly detectable by flow cytometry. 
Another study investigating the relations between CDKN2A mutations and single/multiple 
primary melanomas in North-western Italy, reported additional missense mutations 
detected for the first time in an Italian population and the novel Thr77Ala (T77A), never 
described before (Pastorino et al., 2008). 
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CDKN2A mutations were also analyzed in 55 families mainly from Emilia Romagna and 
Marche, in North-central Italy (Landi et al., 2004). A novel mutation, the Leu65Pro (L65P), 
was identified. Structural considerations on p16 tertiary structures suggested that the 
variant could disrupt secondary structures, possibly resulting in a small spatial distortion. 
The PolyPhen calculations failed to predict an impact of the mutation on protein function. 
Therefore, a yeast two hybrid system was employed and a decrease of about 50% in the 
binding of L65P to CDK4, compared to the wild-type p16 was observed. Being the leucine at 
position 65 not conserved across species and considering that molecular modelling 
suggested only a little effect on this amino acid substitution on protein structure, the modest 
reduction in CDK4 binding of L65P is very reasonable. 
Obviously, not every CDKN2A missense variant necessarily predisposes to melanoma or 
exerts a pathogenic effect on protein function. In this regard, it was suggested that the 
Ala148Thr (A148T) variant, located in the fourth ankyrin repeat domain of p16, could be a 
low penetrance melanoma predisposing allele in a Polish population. To determine the role 
of the A148T on melanoma risk, this allele was genotyped in French and Italian population 
(Spica et al., 2006). Although discordant data were previously reported in different series of 
melanoma patients, the study showed no association of the A148T and melanoma risk.  
Other CDKN2A missense mutations have been identified in Italy, although at low 
frequencies and are reported in Figure 6. 
5.1.3 Mutations in p14 
Mutations in p14 are less frequent compared to those involving p16, also in Italy. While 
mutations laying in exon 1ǃ specifically target p14 only, mutations occurring in the shared 
exon 2 of CDKN2A can potentially affect both p16 and p14, as exemplified by the case of the 
Asn71Ile (N71I) missense mutation, already discussed (Fargnoli et al., 1998). The N71I is 
originated by the 212 A>T nucleotide substitution in exon 2, that converts an asparagine to 
an isoleucine, within the p16 reading frame. The A>T base change also modifies the coding 
region of the p14 transcript, causing the substitution of a gluthamine with a histidine.  
In a case-case study matching amelanotic and pigmented melanoma, the p14 g.193+1 G>A 
germline mutation was detected for the first time in Italy, in a family with five melanoma 
cases and a neural system tumour (Ghiorzo et al., 2009). The g.193+1 G>A was previously 
described to occur in a mutation hotspot at the p14ARF splice site and to be associated with 
aberrant splicing (Harland et al., 2005). By a research group operating in Central Italy, and 
studying 155 either familial or sporadic multiple primary melanoma cases, p14 mutations 
were identified in three unrelated melanoma pedigrees, and no mutations were found in 
sporadic patients (Binni et al., 2010). Two of these families harboured the g.193 + 1 G>A 
mutation, while the third family was positive for the g.161 G>A variant, that resulted in the 
p.Arg54His (R54H) amino acid change. The R54H clearly showed co-segregation with the 
disease and was classified as deleterious by in silico analysis, since the substituted residue is 
highly conserved among species. 
CDKN2A missense mutations detected in Italian melanoma-prone families are listed with 
their main features in Table 1. 
5.1.4 CDKN2A rearrangements analysis  
Given that point mutations have a relatively low frequency in familial melanoma, it is 
possible that other types of CDKN2A alterations, not detectable by routine PCR-based 
methods, might be involved in a fraction of melanoma cases. 
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To assess the role of CDKN2A large, quantitative alterations in the Italian population, 124 
melanoma families without detectable CDKN2A or CDK4 point mutations were screened by 
Multiplex Ligation-dependent Probe Amplification (MLPA) and real-time quantitative PCR 
(Vignoli et al., 2008). This study, involving different Italian centres, reported that no gross 
rearrangements in the CDKN2A coding regions and in the p16-specific promoter were 
present. In five samples a 6 bp deletion was found in proximity of the promoter region of 
exon 1ǃ, but further investigations likely indicated it as a low frequency polymorphism, not 
implicated in disease predisposition. 
Similar results were obtained by Binni et al. (2010) on additional melanoma kindreds, thus 
confirming that CDKN2A rearrangements are an infrequent mechanism for melanoma 
predisposition in Italy, in agreement with data described in other European countries, 
reporting that only 2.1% of mutation carriers harboured large CDKN2A rearrangements 
(Lesueur et al., 2008). 
 
 
Fig. 6. CDKN2A missense mutation pattern in 208 Italian melanoma families. 
An overall mutation frequency of 33% was determined. The frequency at which the single 
mutations occurred in positive-families is shown, with the number of carrier families in 
brackets (data extracted from Bruno et al., 2009).  
5.1.5 CDK4 mutations 
As mentioned before, CKD4 mutations are extremely rare:  a CDK4 missense mutation in 
exon 7, converting the arginine 240 in glutamine (Arg240Gln), was identified (Landi et al., 
2004). The mutation was found in the proband and also in two unaffected relatives. 
Furthermore, in a molecular analysis on subjects with familial and/or multiple primary 
melanoma, the Arg24His was detected in a family, presenting several melanoma cases 
(Majore et al., 2008). 
5.2 Contribution of low penetrance genes and/or other risk factors to melanoma 
susceptibility in Italy 
As already mentioned, a familial aggregation in a Mediterranean country like Italy is 
suggestive of an inherited predisposition (Calista et al., 2000). Moreover, melanoma in a 
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population with a wide range of pigmentary phenotypes, small sized nevi, and intense sun 
exposure may reveal susceptibility pathways specific for this population. Since no evidence of 
linkage to other loci for melanoma susceptibility in Italian CDKN2A-negative families was 
reported (Kerstann et al., 2008; Landi et al., 2004), it is likely that, in some Italian regions, 
clustering of cutaneous malignant melanoma cases might also be the result of a combination of 
multiple low penetrance alleles and/or shared sun exposure habits. The MC1R gene is a major 
determinant of skin phototype and pigmentary characteristics, such as skin, hair and eye 
colour, that together with exposure to environmental ultraviolet radiation, are the main 
modulators of individual melanoma risk. Pigmentation and, consequently, sun sensitivity are 
polygenic traits and several variant alleles have been identified in different regulatory genes 
(Duffy et al., 2010; Fernandez et al., 2009). Up to now, a national Italian work summarizing the 
impact of these genes and environmental/physiological factors on melanoma risk is still 
lacking, while a puzzle of information coming from several Italian regions is mounting, giving 
only a partial description of the various contributing factors. On the other hand, despite 
lacking a view of the whole Italian situation, several authors suggest that this might be the 
right way forward for a correct estimate of low penetrance gene effects, since mutation 
frequency for any candidate cancer gene needs to be evaluated in each specific geographical 
area (Casula et al., 2007). 
 
Exon DNA change 
p16INK4A 
change 
p14ARF 
change 
References 
1ǂ c.68G>A p.Gly23Asp / Fargnoli et al., 1998; 
Scaini et al., 2009 
1ǂ c.67G>A p.Gly23Ser / Gensini et al., 2007 
1ǂ c.71G>C p.Arg24Pro / Harland et al., 1997; 
Fargnoli et al., 1998 
1ǂ c.79G>T p.Glu27X / Ghiorzo et al., 2006 
1ǂ c.142C>A p.Pro48Thr / Della Torre et al., 2001 
1ǃ g.161G>A / p.Arg54His Binni et al., 2010 
2 c.172C>T p.Arg58X p.Pro72Leu Bruno et al., 2009 
2 c.194T>C p.Leu65Pro p.= (Ala79) Landi et al.,  2004 
2 c.202_203GC>TT p.Ala68Leu p.Arg82Leu Bruno et al., 2009 
2 c.212A>T p.Asn71Ile p.Gln85His Fargnoli et al., 1998 
2 c.229A > G p.Thr77Ala p.His91Arg Pastorino et al., 2008 
2 N.A. p.Ala86Thr N.A. Bruno et al., 2009 
2 c.281T>C p.Leu94Pro p.= (Ala108) Bruno et al., 2009 
2 c.301G>T p.Gly101Trp p.Arg115Leu Ghiorzo et al., 1999 
2 c.341C>T p.Pro114Leu p.= (Ala128) Fargnoli et al., 1998 
2 c.377T>A p.Val126Asp / Bruno et al., 2009 
2 c.379G>C p.Ala127Pro / Bruno et al., 2009 
Table 1. Pathogenic CDKN2A missense mutations in Italy (N.A.: Not Available in literature).  
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5.2.1 North-western Italy 
The purpose of a recent study (Pastorino et al., 2008) was the analysis of the contribution of 
CDKN2A mutations and MC1R variants to the development of Multiple Primary Melanoma 
(MPM) versus Single Primary Melanoma (SPM) in the population of two different towns of 
North-western Italy. As for MC1R, which is the topic of the present paragraph, thirty 
different non-synonymous variants were found with an overall allele frequency of 56.32% in 
MPM patients and 44.85% in SPM patients. In both MPM and SPM patients, V60L and 
R151C were the most frequently detected variants. Five novel variants (R67W, L100P, 
D184G, I221T and 1339 + 5 C >T) and two other novel variants (A149T and V156A) were 
detected in the MPM and in the SPM cases, respectively. No association was observed 
between the presence of MC1R variants and age at diagnosis. Compared to the SPM 
patients, MPM cases had a 2-fold increased likelihood of being MC1R variant carriers and a 
higher probability of carrying two or more variants, as reported by Kanetsky et al. (2006) in 
their large multicenter population-based study. 
Finally, the analysis showed no specific association between the variant type and the 
number of CMs (one, two or more). This finding suggested that the presence of at least one 
MC1R variant, regardless of whether it is a R or a r variant, may influence the probability of 
developing two or more CMs, independently of the CDKN2A mutation status. This 
consideration was supported also by the results on the association between phenotypic 
characteristics and prevalence and type of MC1R variants: unexpectedly, the r rather than 
the R variants were associated with light eyes and hair. Fair skin was significantly 
associated with both r and R variants. At the very end, the results on MC1R variants in 
SPM/MPM patients suggest that, in this population, the number rather than the type of 
MC1R variants increases the risk of developing MPM. 
5.2.2 North-eastern Italy  
A case–control study including 183 incident cases of any stage and 179 controls was 
conducted in North-eastern Italy to identify important risk factors and determine how their 
combinations affected risk in a Mediterranean population (Landi et al., 2001). Presence of 
dysplastic nevi, low propensity to tan, light eye, and light skin colour were significantly 
associated with melanoma risk after adjustment for age, gender and pigmentation 
characteristics, showing the need of preventive advice against melanoma in these 
populations. According to the combination of these factors, a relative risk range from 1 to 
98.5 was found. Moreover, light skin colour, high number of sunburns with blistering, and 
low propensity to tan were significantly associated with melanoma thickness, possibly 
indicating that individuals with these characteristics underestimate their risk and seek 
attention when their lesion is already advanced. 
5.2.3 Central Italy 
A work by Fargnoli and coll. (2006) investigated the contribution of the MC1R genotype to 
the risk of sporadic cutaneous melanoma in a population of Central Italy composed by 100 
patients with sporadic cutaneous melanoma of any stage and 100 unrelated controls. All 
high-penetrance R variants of MC1R combined conferred a 2.5-fold increased risk of 
melanoma, and a significant increase in melanoma risk associated with high-penetrance R 
variants was observed mainly in the presence of clinically atypical nevi, more than 50 
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melanocytic nevi and prolonged UV exposure habits. Consistent with other studies, the 
R151C allele was significantly associated with melanoma risk, conferring a 2.9-fold higher 
risk. Interestingly, D294H was detected only in melanoma patients, and not in controls, 
although a larger sample size would be required to achieve statistical significance. Finally, 
the data confirmed the role of high penetrance R variants in the genetic predisposition to 
sporadic melanoma in an Italian population. 
5.2.4 Southern Italy 
Oncogenic BRAF signalling was demonstrated to interfere with the CDKN2A activity. A 
sustained expression of the mutated BRAF protein induces p16 expression and cell cycle 
arrest, indicating that both BRAF and CDKN2A pathways are functionally associated 
(Michaloglou et al., 2005). Finally, inherited mutations of the BRCA2 gene give rise to a 
multi-site cancer phenotype which includes ocular and cutaneous melanomas in addition to 
the main predisposition to breast (in females and males) and ovarian cancers. The work of 
Casula and coll. (2007) tried to assess the likelihood of identifying CDKN2A mutations in 
patients, belonging to Southern Italy or Sardinia, with histologically-proven diagnosis of 
melanoma, included regardless of age at diagnosis, family history status, and disease 
features. 
The authors made also a final comparison between prevalence of CDKN2A germline 
mutations within different Italian regions, pooling together data coming from different 
publications: in contrast to a higher frequency of CDKN2A germline mutations observed in 
non-familial cases from Northern Italy, their findings among the same type of patients from 
Southern Italy strongly suggest that the discrepancy in CDKN2A mutation frequency may 
be due to patient origin and/or to the different ‘genetic background’ of the population. 
Molecular analysis was also performed in order to identify any correlation between genetic 
alterations and phenotypic parameters: CDKN2A mutations were more frequent in patients 
with familial history of melanoma compared to patients without. Moreover, age at diagnosis 
was significantly correlated with the presence of a CDKN2A mutation: the mean age of 
onset was significantly lower in carriers of mutations compared to non-carriers.  
To evaluate whether additional candidate genes might be involved in melanoma 
susceptibility, prevalence of germline mutations in BRAF and BRCA2 genes (the other two 
major genes related to melanoma pathogenesis) was assessed in subsets of patients 
originating from different geographical areas within Southern Italy. 
Germline mutations in BRAF and BRCA2 genes were found in Sardinian patients only 
(altogether, 3/116; 2.6%), with no additional alterations in the remaining cases from 
Southern Italy. These findings strongly confirmed that mutation frequency for any 
candidate cancer gene needs to be evaluated in each geographical area. 
6. Conclusions 
Familial melanoma has proven to be a disease with a heterogeneous etiology, associated 
with mutations in susceptibility genes. Several high and moderate/low risk genes have now 
been identified. CDKN2A remains the most important high risk gene in melanoma 
development; other predisposition genes comprise CDK4, MC1R, and a variety of risk 
modifier genes including MTAP, EGF, GST, MDM2 and many others. There is a great 
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interest in the identification of high risk individuals harbouring melanoma-associated gene 
mutations to offer clinical screening and follow up, since early detection and diagnosis are 
the most significant tools in improving melanoma prognosis and outcome. Undoubtedly, 
the identification of new predisposition loci, together with further investigations on gene-
gene and gene-environment interactions will shed light on molecular mechanisms involved 
in melanocyte transformation. Of course, the real challenge of melanoma research relies in 
converting the growing body of information on the disease into effective strategies to 
implement melanoma prevention and treatment in the near future.  
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